An interventional study of Zinc Supplement in Older Medical Patients, sponsored by Herlev Hospital. Recruiting at 1 site in Denmark. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-09-24.
Sponsored by Herlev Hospital · Not applicable, Interventional, and Treatment
The hypothesis is that a daily supplement of 22 mg of zinc over 12 months can reduce in-flammatory biomarkers in acutely hospitalized older adults aged ≥ 65 years.
The aims are to determine, in acutely hospitalized older adults aged ≥ 65 years, if a daily supplement of 22 mg of zinc over 12 months compared to control can decrease inflammato-ry biomarkers, reduce symptoms of self-reported infection, reduce readmission and mortali-ty, increase QoL, increase physical performance, investigate potential adverse events to zinc supplement, and the changes in inflammatory biomarkers. It will also be studied if albumin-corrected zinc in plasma is a more accurate method for assessing zinc status than ordinary plasma zinc.
Herlev Hospital is the lead sponsor of 201 studies on the registry; 24 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Standard treatment
22 mg zinc supplementation daily for 12 months
Dietary Supplement: Zinc Supplement
22 mg Zinc supplementation daily for 12 months
inflammation 6 months
To evaluate the difference between the groups in plasma concentrations of IL-6 during the first 6-months. Endpoints: Plasma concentration of IL-6 (pg/ml) from baseline to 6 months
Time frame: 6 months
Blood samples indicating metabolic status and risk factors
Between group difference in change in triglycerids (mmol/L)
Time frame: 3 month, 6 month, 12 month
Blood samples indicating metabolic status and risk factors
Between group difference in change in cholesterol (mmol/L)
Time frame: 3 month, 6 month, 12 month
Blood samples indicating metabolic status and risk factors
Between group difference in change in HbA1c (mmol/mol)
Time frame: 3 month, 6 month, 12 month
Blood samples indicating metabolic status and risk factors
Between group difference in change in albumin corrected zinc (μmol/L).
Time frame: 3 month, 6 month, 12 month
Patient reported Outcomes
Between group difference in change in Quality of life measured with EQ5D, and selfreported infections assessed with a homemaid, not validated questionnare.
Time frame: 3,6, and 12 months
Bodycomposition
between group difference in change in fat mass (kg) and muscle mass (kg) assessed with Bioimpedance analysis- BIA meassured at Baseline and after 3, 6 and 12 months
Time frame: 3, 6, and 12 months
Physical performance
between group difference in change in chair stand test 30second
Time frame: 3,6, and 12 month
Physical performance
between group difference in change in handgrip strength (kg)
Time frame: 3,6, and 12 month
Nutrition and zinc intake
estimating zinc intake using 24 hour recall assessment of nutritional intake. Assessing nutritional status with the Patient Generated Subjective Global Assessment (PG-SGA)
Time frame: 3,6, and 12 months
Inflammation changes at 12 months
Between group difference in change in IL6 (pg/ml), IL8 (pg/ml), YKL-40 (pg/ml) (IL6 at 6 months are primary outcomes)
Time frame: 3, 6, and 12 months
Methods for assessing zinc: Free zinc binding capacity(μmol/L) vs. plasma zinc(μmol/L) (with and without adjustments for albumin)
Evaluating the best way to assess zinc status in humans, and the association to occurring infections and readmissions
Time frame: 3, 6, and 12 months
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2026 (actual). Primary completion is estimated for May 2027, 11 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Zinc Supplement